PDCD1 and melanoma: Some studies have demonstrated that inhibition of phosphoinositide 3-kinase (PI3K-γ) in macrophages differentiated from tumour-MDSCs can enhance the immunotherapeutic effects of PD-1 inhibitors in mouse models of melanoma [242, 243].